Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joseph W. Kim, Rana R. McKay, Mary-Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard Joseph Appleman, Primo Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn Bubley, Eliezer Mendel Van Allen, Ying Huang, Zhenwei Zhang, Massimo Loda, Geoffrey Shapiro, Patricia LoRusso, S. Percy Ivy, Daniel Peter Petrylak
Institutions: Yale Cancer Center, University of California San Diego, Moores Cancer Center, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, The Ohio State University, University of Pittsburgh Medical Center, University of California, Davis, Wayne State University, Moffitt Cancer Center, Virginia Commonwealth University Medical Center, Beth Israel Deaconess Medical Center, Weill Cornell Medicine, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3006887019